{"product_id":"2024-asco-annual-meeting","title":"2024 ASCO Annual Meeting","description":"2024 ASCO Annual Meeting The American Society of Clinical Oncology assumes no responsibility for errors or omissions in this publication. The reader is advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify the dosage, the method and duration or administration, or contraindications.\u003cbr\u003e\u003cbr\u003eIt is the responsibility of the treating physician or other health care professional, relying on independent experience and knowledge of the patient, to determine drug, disease, and the best treatment for the patient\u003cbr\u003e\u003cbr\u003e \u003cbr\u003e\u003ch3\u003e2024 ASCO Annual Meeting Abstracts\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eGuidetoAbstracts\u003c\/li\u003e\n\u003cli\u003ePlenarySession............................................................................................................................................................................... 1s\u003c\/li\u003e\n\u003cli\u003eSpecialClinicalScienceSymposia................................................................................................................................................ 3s\u003c\/li\u003e\n\u003cli\u003eBreastCancer—Local\/Regional\/Adjuvant.................................................................................................................................... 6s\u003c\/li\u003e\n\u003cli\u003eBreastCancer—Metastatic............................................................................................................................................................ 39s\u003c\/li\u003e\n\u003cli\u003eCareDelivery\/ModelsofCare........................................................................................................................................................ 75s\u003c\/li\u003e\n\u003cli\u003eCentralNervousSystemTumors.................................................................................................................................................. 112s\u003c\/li\u003e\n\u003cli\u003eDevelopmentalTherapeutics—Immunotherapy......................................................................................................................... 138s\u003c\/li\u003e\n\u003cli\u003eDevelopmentalTherapeutics—MolecularlyTargetedAgentsandTumorBiology.................................................................. 188s\u003c\/li\u003e\n\u003cli\u003eGastrointestinalCancer—ColorectalandAnal............................................................................................................................ 234s\u003c\/li\u003e\n\u003cli\u003eGastrointestinalCancer—Gastroesophageal,Pancreatic,andHepatobiliary........................................................................... 270s\u003c\/li\u003e\n\u003cli\u003eGenitourinaryCancer—KidneyandBladder................................................................................................................................ 323s\u003c\/li\u003e\n\u003cli\u003eGenitourinaryCancer—Prostate,Testicular,andPenile............................................................................................................ 355s\u003c\/li\u003e\n\u003cli\u003eGynecologicCancer........................................................................................................................................................................ 388s\u003c\/li\u003e\n\u003cli\u003eHeadandNeckCancer...................................................................................................................................................................424s\u003c\/li\u003e\n\u003cli\u003eHematologicMalignancies—Leukemia,MyelodysplasticSyndromes,andAllotransplant....................................................457s\u003c\/li\u003e\n\u003cli\u003eHematologicMalignancies—LymphomaandChronicLymphocyticLeukemia...................................................................... 481s\u003c\/li\u003e\n\u003cli\u003eHematologicMalignancies—PlasmaCellDyscrasia...................................................................................................................506s\u003c\/li\u003e\n\u003cli\u003eLungCancer—Non–SmallCellLocal-Regional\/SmallCell\/OtherThoracicCancers..............................................................524s\u003c\/li\u003e\n\u003cli\u003eLungCancer—Non–SmallCellMetastatic.................................................................................................................................. 557s\u003c\/li\u003e\n\u003cli\u003eMedicalEducationandProfessionalDevelopment.....................................................................................................................599s\u003c\/li\u003e\n\u003cli\u003eMelanoma\/SkinCancers................................................................................................................................................................ 613s\u003c\/li\u003e\n\u003cli\u003ePediatricOncology.........................................................................................................................................................................642s\u003c\/li\u003e\n\u003cli\u003ePrevention,RiskReduction,andGenetics...................................................................................................................................662s\u003c\/li\u003e\n\u003cli\u003eQualityCare\/HealthServicesResearch........................................................................................................................................692s\u003c\/li\u003e\n\u003cli\u003eSarcoma........................................................................................................................................................................................... 739s\u003c\/li\u003e\n\u003cli\u003eSymptomScienceandPalliativeCare..........................................................................................................................................762s\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e\u003ca href=\"https:\/\/s3.amazonaws.com\/files.oncologymeetings.org\/prod\/s3fs-public\/2024-05\/AM24-Abstracts.pdf\"\u003eher link of guide\u003c\/a\u003e\u003c\/h3\u003e\n\u003ca href=\"https:\/\/s3.amazonaws.com\/files.oncologymeetings.org\/prod\/s3fs-public\/2024-05\/AM24-Abstracts.pdf\"\u003ehttps:\/\/s3.amazonaws.com\/files.oncologymeetings.org\/prod\/s3fs-public\/2024-05\/AM24-Abstracts.pdf\u003c\/a\u003e\n\u003cbr\u003e\u003ch1 class=\"h2\"\u003e2024 ASCO Annual Meeting  American Society of Clinical Oncology (ASCO) 2024 Annual Meeting\u003c\/h1\u003e\n\u003ch3\u003e\u003cspan style=\"color: #0000ff;\"\u003e\u003ca href=\"https:\/\/meetings.asco.org\/meetings\/2024-asco-annual-meeting\/316\/program-guide\/scheduled-sessions\" style=\"color: #0000ff;\"\u003ehttps:\/\/meetings.asco.org\/meetings\/2024-asco-annual-meeting\/316\/program-guide\/scheduled-sessions\u003c\/a\u003e\u003c\/span\u003e\u003c\/h3\u003e\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e\u003ca href=\"https:\/\/meetings.asco.org\/meetings\/2024-asco-annual-meeting\/316\/program-guide\/my-agenda\"\u003ehttps:\/\/meetings.asco.org\/meetings\/2024-asco-annual-meeting\/316\/program-guide\/my-agenda\u003c\/a\u003e","brand":"meducours","offers":[{"title":"Default Title","offer_id":42954390962274,"sku":"MED-AMB02509","price":85.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/2024-ASCO-Annual-Meeting-1.webp?v=1779375201","url":"https:\/\/meducourse.com\/products\/2024-asco-annual-meeting","provider":"Meducourse","version":"1.0","type":"link"}